4-Cyanophenylboronic acid

We are 4-Cyanophenylboronic acid CAS:126747-14-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:  4-Cyanophenylboronic acid
CAS.NO: 126747-14-6
Synonyms:4-Cyanophenylboronic Acid
4-Cyanobenzeneboronic Acid
(p-Cyanophenyl)boronic acid 
4-Cyanophenylboric acid
(4-cyanophenyl)boronic acid
 
Molecular Formula: C7H6BNO2
Molecular Weight: 146.93900
 
Physical and Chemical Properties:
Density: 1.25g / cm3
Boiling point: 355.9ºC at 760mmHg
Melting point:> 350 ° C (lit.)
Flash point: 169ºC
Refractive index: 1.559
 
Specification:
Appearance:White to yellow powder
Purity:>98%
 
Packing:20 kg/drum, can also be packaged according to customer requirements
Storage:Store at 0-6 ºC.Sealed at room temperature and protected from light, ventilated and dry.
Application:For cross-coupling reactions.

4-Cyanophenylboronic acid


Related News: We purchase the raw materials from raw material or chemical product manufacturers both in Japan and internationally. Clorhidrato de ácido (2-metilpiridin-4-il) borónico CAS:861905-97-7 This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?1-(4-Hydrazinophenyl)methyl-1,2,4-triazole CAS:212248-62-9 This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?HC VIOLET NO. 2 CAS:104226-19-9 This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?In recent years, China’s bulk drug companies have gradually completed the upgrade of the product structure of bulk raw materials to specialty raw materials and intermediates. The industry’s leading companies have further developed the research and development layout of high-barrier generic pharmaceutical raw materials with multiple patents that have not yet expired.

Related Products
Product Name
4-Fluorobenzotrifluoride View Details
exo-3,6-Methylene-1,2,3,6-tetrahydrophthalic anhydride View Details
N-methyl-N-[(3R,4R)-4-methylpiperidin-3-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine View Details
1-Chlorocarbonyl-3-Methanesulfonyl-2-Imidazolidinone manufacturer 1-Bromo-4-iodobenzene manufacturer 5-bromo-4-methylpyridine-2-carbonitrile manufacturer (2S,3R)-3-Amino-2-hydroxy-4-phenylbutyric acid manufacturer tert-butyl N-[(2R)-1-hydroxy-3-phenylmethoxypropan-2-yl]carbamate manufacturer